Abstract
The development of antiviral drugs has progressed through several stages. We have witnessed within the past few years a major breakthrough in antiviral chemotherapy, because selectivity can now be based on a qualitative exploitation of unique virus enzymic activities. Thus, today we have several antiviral agents which have little or no host cell toxicity, because they are uniquely or preferentially activated (phosphorylated) by the herpesvirus encoded thymidine kinase which is present only in the infected cell. Examples include: 9-(2′ hydroxyethoxymethyl)guanine, 5-ethyl-2′-deoxyuridine, 5-propyl-2′ -deoxyuridine, 5-iodo-5′-amino-2′, 5′-dideoxyuridine, 5-(2-bromovinyl)-2′-deoxyuridine, 5-methoxymethyl-2′-deoxyuridine and 2′-fluoro-5-iodo-arabinosyl cytosine.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
